Trial Profile
Study of apatinib combined with chemotherapy in the platinum resistant / refractory recurrent epithelial ovarian cancer, tubal cancer or peritoneal cancer
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 04 Jul 2018
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 04 Jul 2018 New trial record